Observational study on intracellular uptake molecules in chronic myeloid leukemia patients receiving tyrosine-kinase inhibitors

Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by San Salvatore Hospital of L'Aquila. Primary endpoints: Frequency of polymorphisms of genes involved in intracellular uptake and Association between gene polymorphisms and clinical or pharmacologic outcomes. Started Mar 2012; status: active.